FDA Official Tells Industry How To Avoid Excipient Trip-Ups When Filing ANDAs
Executive Summary
FDA official tells generics firms how to avoid letting excipient filing mistakes prompt ANDA derailments via refuse-to-receive letters.
You may also be interested in...
US FDA Guidance Explains Upcoming Enhancements To Inactive Ingredients Database
Next year, generic drug manufacturers will finally get some of the improvements they have been asking for in the US FDA’s Inactive Ingredient Database, such as being able to access the maximum daily intake (MDI) for each excipient. This information is helpful to industry in formulating products.
Program Participants Urge The FDA To Adopt Some Pharmaceutical Quality Metrics And Avoid Others
Site-based metrics praised; lot acceptance rates, invalidated OOS rates discouraged. Agency official admits some proposed metrics were “not the best.”
EU GMP Annex I Is A Top Priority For EMA While Industry Has Lingering Concerns
Questions about contamination control strategy raised as European Medicines Agency makes EU GMP Annex I revision a top priority in its 2021 work plan.